DXCM Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of 23.47% compared to DexCom, Inc.'s net margin of 31.72%. DexCom, Inc.'s return on equity of 30.94% beat Eli Lilly & Co.'s return on equity of 106.26%.

DexCom, Inc. has a consensus price target of $84.77, signalling upside risk potential of 30.72%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,045.59 which suggests that it could grow by 1.16%. Given that DexCom, Inc. has higher upside potential than Eli Lilly & Co., analysts believe DexCom, Inc. is more attractive than Eli Lilly & Co..

DexCom, Inc. has a beta of 1.513, which suggesting that the stock is 51.265% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

DexCom, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. DexCom, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DexCom, Inc. quarterly revenues are $1.2B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. DexCom, Inc.'s net income of $283.8M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, DexCom, Inc.'s price-to-earnings ratio is 36.09x while Eli Lilly & Co.'s PE ratio is 51.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom, Inc. is 5.85x versus 15.86x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 23.47% compared to DexCom, Inc.'s net margin of 33.68%. DexCom, Inc.'s return on equity of 30.94% beat Merck & Co., Inc.'s return on equity of 39.63%.

DexCom, Inc. has a consensus price target of $84.77, signalling upside risk potential of 30.72%. On the other hand Merck & Co., Inc. has an analysts' consensus of $105.35 which suggests that it could grow by 3.01%. Given that DexCom, Inc. has higher upside potential than Merck & Co., Inc., analysts believe DexCom, Inc. is more attractive than Merck & Co., Inc..

DexCom, Inc. has a beta of 1.513, which suggesting that the stock is 51.265% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

DexCom, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.17% to investors and pays a quarterly dividend of $0.81 per share. DexCom, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DexCom, Inc. quarterly revenues are $1.2B, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. DexCom, Inc.'s net income of $283.8M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, DexCom, Inc.'s price-to-earnings ratio is 36.09x while Merck & Co., Inc.'s PE ratio is 13.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom, Inc. is 5.85x versus 4.03x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 23.47% compared to DexCom, Inc.'s net margin of 38.89%. DexCom, Inc.'s return on equity of 30.94% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

DexCom, Inc. has a consensus price target of $84.77, signalling upside risk potential of 30.72%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $768.36 which suggests that it could grow by 6.18%. Given that DexCom, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe DexCom, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

DexCom, Inc. has a beta of 1.513, which suggesting that the stock is 51.265% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

DexCom, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. DexCom, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

DexCom, Inc. quarterly revenues are $1.2B, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. DexCom, Inc.'s net income of $283.8M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, DexCom, Inc.'s price-to-earnings ratio is 36.09x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom, Inc. is 5.85x versus 5.60x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

UnitedHealth Group, Inc. has a net margin of 23.47% compared to DexCom, Inc.'s net margin of 2.25%. DexCom, Inc.'s return on equity of 30.94% beat UnitedHealth Group, Inc.'s return on equity of 17.57%.

DexCom, Inc. has a consensus price target of $84.77, signalling upside risk potential of 30.72%. On the other hand UnitedHealth Group, Inc. has an analysts' consensus of $388.52 which suggests that it could grow by 14.37%. Given that DexCom, Inc. has higher upside potential than UnitedHealth Group, Inc., analysts believe DexCom, Inc. is more attractive than UnitedHealth Group, Inc..

DexCom, Inc. has a beta of 1.513, which suggesting that the stock is 51.265% more volatile than S&P 500. In comparison UnitedHealth Group, Inc. has a beta of 0.428, suggesting its less volatile than the S&P 500 by 57.182%.

DexCom, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group, Inc. offers a yield of 2.54% to investors and pays a quarterly dividend of $2.21 per share. DexCom, Inc. pays -- of its earnings as a dividend. UnitedHealth Group, Inc. pays out 52.75% of its earnings as a dividend. UnitedHealth Group, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DexCom, Inc. quarterly revenues are $1.2B, which are smaller than UnitedHealth Group, Inc. quarterly revenues of $113.2B. DexCom, Inc.'s net income of $283.8M is lower than UnitedHealth Group, Inc.'s net income of $2.5B. Notably, DexCom, Inc.'s price-to-earnings ratio is 36.09x while UnitedHealth Group, Inc.'s PE ratio is 17.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom, Inc. is 5.85x versus 0.71x for UnitedHealth Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.